Search results
Results from the WOW.Com Content Network
Buspirone appears to be relatively benign in cases of single-drug overdose, although no definitive data on this subject appear to be available. [31] In one clinical trial , buspirone was administered to healthy male volunteers at a dosage of 375 mg/day, and produced side effects including nausea , vomiting , dizziness , drowsiness , miosis ...
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4]
The only exception to this rule is umespirone, which has a very long duration with a single dose lasting as long as 23 hours. [45] Unfortunately, umespirone has not been commercialized. Although never commercially produced, Bristol-Myers Squibb applied for a patent on October 28, 1993, and received the patent on July 11, 1995, for an extended ...
Keppra (levetiracetam) – an anticonvulsant drug which is sometimes used as a mood stabilizer and has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder, and Alzheimer's disease; Klonopin – anti-anxiety and anti-epileptic medication of the benzodiazepine class
The new guidelines, released in late October 2024, state that patients 65 or older, as well as individuals who are moderately or severely immunocompromised, should get a booster every six months ...
Cerebrovascular accident (stroke); Myocardial infarction (heart attack); Cardiomyopathy; Congestive heart failure; Bradycardia; Dysphoria; Hallucinations; Feelings of ...
[1] [3] [4] [5] The scores shown are the mean total depression scores on the MADRS over 6 weeks. Only 124/156 patients completed 6 weeks of Auvelity while 150/162 patients completed 6 weeks of placebo, consistent with a high rate of adverse reactions. [4] [5] [2] Dextromethorphan/bupropion is approved for the treatment of major depressive ...
As the number of people 65 and older is predicted to nearly double in the next 40 years and reach 80 million by 2040, some experts predict that there won't be enough programs in place to support them.